
    
      The performance of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen (CEA)
      monoclonal antibody intraoperative imaging agent for the delineation of primary and recurrent
      tumor and metastases in patients undergoing curative surgery for colorectal cancer will be
      compared to that of standard "white light" visualization in a multicenter, open-label,
      randomized, controlled, parallel arms clinical study.
    
  